Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?
Fabi A, Ciccarese M, Scagnoli S, Russillo M, Schettini F, Buono G, Lorusso V, Cannita K, Arpino G, Stani S, Palleschi M, Rossello R, Sarobba G, Fabbri A, Giampaglia M, Pellegrini P, Adamo V, Morelli F, Barberi V, Ferretti G, Catania G, Pisegna S, Cognetti F, Giannarelli D.
Fabi A, et al. Among authors: pellegrini p.
Oncology. 2021 Dec 7. doi: 10.1159/000521252. Online ahead of print.
Oncology. 2021.
PMID: 34875670